Literature DB >> 16585605

Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo.

Ariane Chapgier1, Robert F Wynn, Emmanuelle Jouanguy, Orchidée Filipe-Santos, Shenying Zhang, Jacqueline Feinberg, Kay Hawkins, Jean-Laurent Casanova, Peter D Arkwright.   

Abstract

The autosomal recessive form of human complete Stat-1 deficiency is a rare disorder, thus far reported in two unrelated patients, both of whom developed disseminated bacillus Calmette-Guérin (BCG) and subsequently died of viral illnesses before detailed studies of the condition could be performed. It is associated with impaired cellular responses to both IFN-gamma and IFN-alphabeta via Stat-1-containing complexes. We describe a third patient with complete Stat-1 deficiency and disseminated BCG infection, who died 3 mo after bone marrow transplantation. The patient's EBV-transformed B cells did not express Stat-1 protein and did not activate Stat-1-containing transcription factors. We also report the ex vivo responses of a Stat-1-deficient patient's fresh blood cells to IFN-gamma and the in vitro responses of a SV40-transformed fibroblastic cell line to IFN-gamma and IFN-alphabeta. There was no response to IFN-gamma in terms of IL-12 production and HLA class II induction, accounting for vulnerability to BCG. Moreover, IFN-alphabeta did not suppress HSV and vesicular stomatitis virus replication in fibroblasts, although in vivo the patient was able to successfully clear at least some viruses. This study broadens our understanding of complete Stat-1 deficiency, a severe form of innate immunodeficiency. Stat-1 deficiency should be suspected in children with severe infections, notably but not exclusively patients with mycobacterial or viral diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585605     DOI: 10.4049/jimmunol.176.8.5078

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  83 in total

Review 1.  Human genetic susceptibility to Candida infections.

Authors:  Theo S Plantinga; Melissa D Johnson; William K Scott; Leo A B Joosten; Jos W M van der Meer; John R Perfect; Bart Jan Kullberg; Mihai G Netea
Journal:  Med Mycol       Date:  2012-06-04       Impact factor: 4.076

2.  Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies.

Authors:  Itai M Pessach; Jose Ordovas-Montanes; Shen-Ying Zhang; Jean-Laurent Casanova; Silvia Giliani; Andrew R Gennery; Waleed Al-Herz; Philip D Manos; Thorsten M Schlaeger; In-Hyun Park; Francesca Rucci; Suneet Agarwal; Gustavo Mostoslavsky; George Q Daley; Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2010-12-24       Impact factor: 10.793

3.  PRDM16 represses the type I interferon response in adipocytes to promote mitochondrial and thermogenic programing.

Authors:  Megan Kissig; Jeff Ishibashi; Matthew J Harms; Hee-Woong Lim; Rachel R Stine; Kyoung-Jae Won; Patrick Seale
Journal:  EMBO J       Date:  2017-04-13       Impact factor: 11.598

Review 4.  Natural killer cells in immunodefense against infective agents.

Authors:  Nicolas Zucchini; Karine Crozat; Thomas Baranek; Scott H Robbins; Marcus Altfeld; Marc Dalod
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

Review 5.  The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus.

Authors:  Lisi Amsler; Marieke Verweij; Victor R DeFilippis
Journal:  J Mol Biol       Date:  2013-09-05       Impact factor: 5.469

Review 6.  Incomplete penetrance in primary immunodeficiency: a skeleton in the closet.

Authors:  Conor Gruber; Dusan Bogunovic
Journal:  Hum Genet       Date:  2020-02-17       Impact factor: 4.132

7.  Heterozygosity for the Y701C STAT1 mutation in a multiplex kindred with multifocal osteomyelitis.

Authors:  Osamu Hirata; Satoshi Okada; Miyuki Tsumura; Reiko Kagawa; Mizuka Miki; Hiroshi Kawaguchi; Kazuhiro Nakamura; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Yoshihiro Takihara; Masao Kobayashi
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

8.  Pyogenic bacterial infections in humans with MyD88 deficiency.

Authors:  Horst von Bernuth; Capucine Picard; Zhongbo Jin; Rungnapa Pankla; Hui Xiao; Cheng-Lung Ku; Maya Chrabieh; Imen Ben Mustapha; Pegah Ghandil; Yildiz Camcioglu; Júlia Vasconcelos; Nicolas Sirvent; Margarida Guedes; Artur Bonito Vitor; María José Herrero-Mata; Juan Ignacio Aróstegui; Carlos Rodrigo; Laia Alsina; Estibaliz Ruiz-Ortiz; Manel Juan; Claudia Fortuny; Jordi Yagüe; Jordi Antón; Mariona Pascal; Huey-Hsuan Chang; Lucile Janniere; Yoann Rose; Ben-Zion Garty; Helen Chapel; Andrew Issekutz; László Maródi; Carlos Rodriguez-Gallego; Jacques Banchereau; Laurent Abel; Xiaoxia Li; Damien Chaussabel; Anne Puel; Jean-Laurent Casanova
Journal:  Science       Date:  2008-08-01       Impact factor: 47.728

9.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

10.  B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans.

Authors:  Danielle T Avery; Elissa K Deenick; Cindy S Ma; Santi Suryani; Nicholas Simpson; Gary Y Chew; Tyani D Chan; Umamainthan Palendira; Jacinta Bustamante; Stéphanie Boisson-Dupuis; Sharon Choo; Karl E Bleasel; Jane Peake; Cecile King; Martyn A French; Dan Engelhard; Sami Al-Hajjar; Saleh Al-Muhsen; Klaus Magdorf; Joachim Roesler; Peter D Arkwright; Pravin Hissaria; D Sean Riminton; Melanie Wong; Robert Brink; David A Fulcher; Jean-Laurent Casanova; Matthew C Cook; Stuart G Tangye
Journal:  J Exp Med       Date:  2010-01-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.